Myriad Genetics, Inc. (MYGN) Reaches $31.76 After 8.00% Up Move; PATRIZIA IMMOBILIEN AG AUGSBURG ORDINARY (PTZIF) SI Decreased By 2.23%

Myriad Genetics, Inc. (NASDAQ:MYGN) Logo

The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) is a huge mover today! The stock increased 5.97% or $1.79 during the last trading session, reaching $31.76. About 393,076 shares traded. Myriad Genetics, Inc. (NASDAQ:MYGN) has declined 4.31% since March 12, 2018 and is downtrending. It has underperformed by 8.68% the S&P500. Some Historical MYGN News: 23/03/2018 – Myriad Genetics at Company Marketing Hosted By Stephens Inc; 06/03/2018 Myriad Applauds AACU Position Statement on Molecular Testing for Risk Stratification in Prostate Cancer; 12/03/2018 – MYRIAD GENETICS – SUBPOENA CONNECTED WITH INVESTIGATION INTO CLAIMS SUBMITTED FOR PAYMENT UNDER MEDICARE AND MEDICAID; 25/04/2018 – Scott+Scott Attorneys at Law LLP Alerts Investors to the Filing of Securities Class Action Against Myriad Genetics, Inc. (MYGN); 12/03/2018 – MYRIAD GENETICS RECEIVED HHS SUBPOENA ON POSSIBLY FALSE CLAIMS; 23/04/2018 – Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. (MYGN); 16/03/2018 – Myriad Genetics Access Event Set By Stephens Inc. for Mar. 23; 12/03/2018 – MYRIAD GENETICS – NO CLAIMS HAVE BEEN MADE AGAINST CO AT THIS TIME; 07/05/2018 – Landmark Study Shows GeneSight? Test Led to Significant Improvement in Mental Health Outcomes for Patients with Major Depressive Disorder; 12/03/2018 – Myriad Genetics Receives Subpoena From HHSThe move comes after 6 months positive chart setup for the $2.33 billion company. It was reported on Mar, 12 by Barchart.com. We have $34.30 PT which if reached, will make NASDAQ:MYGN worth $186.16M more.

PATRIZIA IMMOBILIEN AG AUGSBURG ORDINARY (OTCMKTS:PTZIF) had a decrease of 2.23% in short interest. PTZIF’s SI was 486,100 shares in March as released by FINRA. Its down 2.23% from 497,200 shares previously. It closed at $21.92 lastly. It is up 0.00% since March 12, 2018 and is . It has underperformed by 4.37% the S&P500.

Analysts await Myriad Genetics, Inc. (NASDAQ:MYGN) to report earnings on May, 14. They expect $0.38 EPS, up 22.58% or $0.07 from last year’s $0.31 per share. MYGN’s profit will be $27.84 million for 20.89 P/E if the $0.38 EPS becomes a reality. After $0.30 actual EPS reported by Myriad Genetics, Inc. for the previous quarter, Wall Street now forecasts 26.67% EPS growth.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company has market cap of $2.33 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It has a 103.79 P/E ratio. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.

More notable recent Myriad Genetics, Inc. (NASDAQ:MYGN) news were published by: Globenewswire.com which released: “Myriad Genetics to Present at Multiple Upcoming Healthcare Conferences – GlobeNewswire” on February 13, 2019, also Nasdaq.com with their article: “Vectra? Study Published in the Journal Current Medical Research & Opinion – Nasdaq” published on February 22, 2019, Nasdaq.com published: “Detailed Research: Economic Perspectives on The Scotts Miracle-Gro, Forum Energy Technologies, Myriad Genetics, Ichor, Adesto Technologies, and Viad — What Drives Growth in Today’s Competitive Landscape – Nasdaq” on February 12, 2019. More interesting news about Myriad Genetics, Inc. (NASDAQ:MYGN) were released by: Nasdaq.com and their article: “Myriad Applauds the American Society of Breast Surgeons New Guidelines Recommending Genetic Testing for All People with Breast Cancer – Nasdaq” published on February 15, 2019 as well as Globenewswire.com‘s news article titled: “Myriad Announces Prequelâ„¢ Prenatal Screen with Expanded Aneuploidy Analysis for all 23 Chromosome Pairs – GlobeNewswire” with publication date: February 11, 2019.

Among 7 analysts covering Myriad Genetics (NASDAQ:MYGN), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. Myriad Genetics had 8 analyst reports since October 10, 2018 according to SRatingsIntel. The firm has “Outperform” rating by Cowen & Co given on Friday, January 4. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) has “Underweight” rating given on Thursday, January 3 by Barclays Capital. The stock has “Hold” rating by Deutsche Bank on Monday, November 5. The rating was upgraded by Goldman Sachs on Friday, November 30 to “Neutral”. The rating was maintained by Morgan Stanley with “Overweight” on Wednesday, October 10. On Wednesday, October 10 the stock rating was upgraded by PiperJaffray to “Overweight”.

Investors sentiment decreased to 1.23 in 2018 Q4. Its down 0.21, from 1.44 in 2018Q3. It is negative, as 30 investors sold Myriad Genetics, Inc. shares while 67 reduced holdings. 29 funds opened positions while 90 raised stakes. 74.41 million shares or 2.06% more from 72.91 million shares in 2018Q3 were reported. Glenmede Communications Na holds 0% in Myriad Genetics, Inc. (NASDAQ:MYGN) or 6,879 shares. Canada Pension Plan Investment Board has 4,100 shares. Great West Life Assurance Can, a Manitoba – Canada-based fund reported 99,142 shares. Tci Wealth Advisors invested 0% in Myriad Genetics, Inc. (NASDAQ:MYGN). Virginia Retirement Systems Et Al invested in 39,700 shares. Frontier Mngmt Communications Limited Liability Com reported 3.22 million shares stake. Cibc Ww Mkts stated it has 7,106 shares or 0% of all its holdings. First Tru Limited Partnership stated it has 0% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN). Us National Bank De accumulated 2,025 shares or 0% of the stock. Matarin reported 0% in Myriad Genetics, Inc. (NASDAQ:MYGN). Assetmark Inc holds 0% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN) for 83 shares. Tudor Inv Et Al stated it has 76,109 shares or 0.04% of all its holdings. Goldman Sachs Group Incorporated accumulated 543,455 shares. First Republic Investment Management Incorporated accumulated 8,470 shares. Clearbridge Invs Limited Com holds 0% or 1,444 shares.

Myriad Genetics, Inc. (NASDAQ:MYGN) Institutional Positions Chart